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chestjournal.orgRegional and/or national severe asthma registries provide valuable country-specific informa-
tion. However, they are often limited in scope within the broader definitions of severe asthma,
have insufficient statistical power to answer many research questions, lack intraoperability to
share lessons learned, and have fundamental differences in data collected, making cross
comparisons difficult. What is missing is a worldwide registry which brings all severe asthma
data together in a cohesive way, under a single umbrella, based on standardized data collection
protocols, permitting data to be shared seamlessly. The International Severe Asthma Registry
(ISAR; http://isaregistries.org/) is the first global adult severe asthma registry. It is a joint
initiative where national registries (both newly created and preexisting) retain ownership of
their own data but open their borders and share data with ISAR for ethically approved research
purposes. Its strength comes from collection of patient-level, anonymous, longitudinal, real-
life, standardized, high-quality data (using a core set of variables) from countries across the
world, combined with organizational structure, database experience, inclusivity/openness, and
clinical, academic, and database expertise. This gives ISAR sufficient statistical power to
answer important research questions, sufficient data standardization to compare across
countries and regions, and the structure and expertise necessary to ensure its continuance and
the scientific integrity and clinical applicability of its research. ISAR offers a unique opportunity
to implement existing knowledge, generate new knowledge, and identify the unknown, there-
fore promoting new research. The aim of this commentary is to fully describe how ISAR may
improve our understanding of severe asthma. CHEST 2020; 157(4):805-814KEY WORDS: ISAR; severe asthmaOptimum treatment of severe asthma
represents a major unmet need. Although it
affects a relatively small proportion of the
asthma population (approximately 5%-10%),
and even less (< 1%) for severe uncontrolled
eosinophilic asthma,1-4 it accounts for
> 50% of the costs attributed to the disease.5
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DOI: https://dthree times the asthma medication costs as
those with persistent disease.6 Despite
improvement in outcomes, severe asthma is
still a cause of mortality.7 There is, therefore,
an unmet need to characterize and classify
these patients with a view to improve
therapy and reduce costs on a global scale.
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severe asthma as “uncontrolled asthma which can result
in risk of frequent severe exacerbations (or death) and/
or adverse reactions to medications and/or chronic
morbidity.” However, in clinical practice, other terms
are often used such as difficult to treat, refractory,
unresponsive or brittle, steroid-dependent, and
treatment-resistant.8-10 This language is reflected in the
European Respiratory Society/American Thoracic
Society Task Force2 definition of severe disease as
“asthma which requires treatment with high-dose
inhaled corticosteroids (ICS) plus a second controller
(and/or systemic corticosteroids) to prevent it from
becoming uncontrolled or which remains uncontrolled
despite this therapy.” Confirmation of good adherence
to therapy, proper inhalation technique, appropriate
management of exposures and comorbidities, and
accurate patient education are further required to
distinguish severe asthma from asthma that is
uncontrolled because of other causes, such as poor
adherence or comorbidities.11,12
Prevalence estimates of severe asthma vary widely from
country to country (ranging from 3.6% in The
Netherlands to 8.1% in Denmark),13-16 a reflection of
different definitions used and difficulties associated with
obtaining reliable figures as a consequence of differences
in access to health care. Reliability of the data is further
confounded by the possibility that patients with severe
asthma may be hidden because of a variety of factors
including a patient’s willingness to live with, or tolerate,
their symptoms and lifestyle limitations,17-19 an
acceptance of the need for frequent courses of oral
corticosteroids as usual rather than exceptional care,
pressure on primary care providers not to refer to
specialist clinics, and/or lack of awareness that the
condition needs specialist attention and intensive
therapy, as well as newer treatment options. Therefore,
the true prevalence of severe asthma may be higher than
that reported in the literature.
Many countries have developed regional and/or national
severe asthma registries to gather information on severe
asthma and to better understand the disease history,
progression, impact, and response to treatment.14,20-26
These registries have provided valuable information on
country-specific epidemiologic patterns, risks, and
treatment benefits, and have enabled safety monitoring of
therapies. However, because of the relatively small size of
the severe asthma population, and their spread over a
wide geographic area,2,3 such registries often have limited
power to answer important research and clinical
questions, and differ in their inclusion criteria and/or806 CHEST Reviewsfocus. Furthermore, because these registries were setup
independently, it is hardly surprising that they reflect
country-specific variability in patient selection, health-
care access, and referral patterns and incorporate
different data fields, ultimately collecting data of variable
quality and completeness. This makes cross comparisons
difficult and large-scale epidemiologic studies
challenging. The discrete and segregated nature of these
local registries means that there is no capacity for
intraoperability with no linkage between them; therefore,
valuable information is not shared in real time and cannot
be contextualized within a global severe asthma
framework until individual registry data are published.
What is missing is a worldwide registry which brings all
severe asthma data together in a cohesive way, under a
single umbrella. Pooling our resources to generate a
centralized severe asthma dataset would permit data to
be shared seamlessly between countries and institutions,
to ultimately gain better insight into severe asthma on a
global scale, covering response to therapies across all
genetic backgrounds. This can be done by opening our
severe asthma registry borders to share information
gathered at the national and regional levels. The process
may be further optimized by standardizing the variables
collected, producing one overarching registry. The
International Severe Asthma Registry (ISAR) (http://
isaregistries.org/) is the first global adult severe asthma
registry. It gathers patient-level, anonymized,
longitudinal, real-life data from preexisting national
registries (and newly established national registries, for
which ISAR provides setup support) for adults with
severe asthma, from countries all over the world. Severe
asthma is defined by ISAR as those patients on Global
Initiative for Asthma Step 5, or those with uncontrolled
asthma on Global Initiative for Asthma Step 4.27,28
Pooling data in this way provides important information
for all stakeholders. With such a large dataset, physicians
gain information not only on patient presentation, but
also knowledge of predictors of treatment success in the
era of personalized medicine and predicted outcomes of
personalized therapies; patients gain a better
understanding of the natural history of their disease,
with their collective data used to inform treatment
guidelines; payers get evidence on how treatments are
used and their effectiveness (both clinical and economic)
in different patient populations; and the pharmaceutical
industry can assess the effectiveness and long-term
safety of therapeutic agents in real life, fulfilling
postmarketing surveillance commitments and
identifying patients for future clinical trials.29[ 1 5 7 # 4 CHES T A P R I L 2 0 2 0 ]
What Does ISAR Bring to Our Understanding
of Severe Asthma?
ISAR contributes to our understanding of severe asthma
in six key areas (Fig 1). It is the first global adult severe
asthma registry, which ultimately will be large enough to
ensure sufficient power to answer numerous important
clinical questions. A pediatric registry is currently in the
planning stages. The data collected by ISAR are
standardized, individualized, and comprehensive. ISAR
has scientific, academic, and ethical oversight providing
confidence in data collection, analysis, and
dissemination, and extensive experience in large data
collection and management. It operates on the principle
of inclusivity and collaboration, continually seeking new
partners and prioritizing relevant research pertinent to
severe asthma. Finally, ISAR is a cross-disciplinary
initiative, holding within it the combined experience of
key thought leaders in severe asthma (physicians and
epidemiologists) and basic scientists, data analysts, and
experts in database management and communication.
Each of these six attributes contribute to ISAR’s overall
aim of improving the care of adults with severe asthma
globally (both in primary and secondary care). This aim
will be achieved via provision of a rich source of real-life
data for scientific research to better understand the
epidemiology, burden, clinical evolution, real-world
safety of new treatment and management patterns of100%
EXPERT
Inclusivity
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Expertise & deliverables
To conduct robust & ethical
scientific studies for publication
in peer-reviewed journals
Figure 1 –What the ISAR brings to our understanding of severe asthma. EDC
chestjournal.orgsevere asthma (exploring differences across health-care
systems), and to assess treatments (in the absence of
comparative randomized controlled trials [RCTs]) and
patient outcomes for severe asthma.
Global Reach
Patients with severe asthma are present over a wide
geographic area. ISAR already partners with 20 national
or regional registries in Europe (Bulgaria, Denmark,
Greece, Ireland, Italy, Netherlands, Spain, and the
United Kingdom), The Americas (United States,
Canada, Columbia, and Mexico), Asia Pacific (Japan,
India, South Korea, and Taiwan) and the Severe Asthma
Web-based Database registry (comprising patient data
from Australia, New Zealand, and Singapore), and the
Middle East (Kuwait, United Arab Emirates, and Saudi
Arabia), with planned expansion to other regions of the
world—including Africa. Some of these local registries
are currently being developed with ISAR involvement.
At the time of writing this report, agreements were in
process with eight countries (Finland, Germany, Iceland,
Norway, Sweden, Singapore, Argentina, and Russia).
Countries newly engaged include Portugal, Estonia,
France, and Brazil, giving ISAR a truly global reach.
ISAR currently comprises data from 7,948 patients with
severe asthma (individual data: n ¼ 7,250; aggregate
data: n ¼ 698), with new data provided quarterly. TheGlobal reach
Partnering with registries
around the world
Quality data
Validated and standardized
using a core set of variables
Organizational structure
Ensuring continuance as
well as ethical & clinically-
appropriate research
Data capture
EDC systems improve efficiency,
reduce workload, time & cost and
enhance data quality
¼ electronic data capture; ISAR¼ International Severe Asthma Registry.
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individual data are prospective for 2,113 patients and
retrospective for 5,137 patients (Fig 2). ISAR is a joint
initiative and would not exist without the data provided
by local registries. Importantly, local registries retain
ownership of their own data, but benefit from ISAR in
terms of the analytic power it provides and cross
comparisons with data from other countries. ISAR also
supports setting up of local registries via provision of a
standardized variables list and resource support in
assessing data quality and/or an electronic data
capturing system. The registry acts as a data custodian,
collecting, collating, exploring, and analyzing
standardized data provided by local registries. Countries
participate by either enabling country data to be
provided directly into ISAR or by allowing country data
to be used for any research conducted under the ISAR
initiative, and approved by ISAR’s governance body.
Quality Data
The value of any global registry derives not only from its
geographic scope and the data it collects, but also from
the quality of that data. Data collected by ISAR is fully
anonymized, and at individual rather than aggregate
level, offering the potential to explore additional, more
thorough, and appropriate analyses per research
question compared with the limited options possible
with aggregate data.30 Patient-level data provide the
opportunity to conduct biostatistical multivariateFigure 2 – Global coverage of the ISAR. Green indicates the current contribu
indicates the countries engaged with ISAR. See Figure 1 legend for expansion
808 CHEST Reviewsanalyses to investigate the potential relationship between
outcome and risk factors, and provide level of risk for a
patient rather than for a group (eg, age group, country)
to track patient progress longitudinally over the course
of time and to analyze response to treatment and
changes in medical management. ISAR’s centralized
analysis model also removes potential for discrepancies
in the methodology of data analyses between countries,
provides the ability to dig further into individual country
data (as part of a multinational dataset), and is a cost-
effective and time-efficient approach. Data collection is
standardized across all ISAR-contributing countries,
using a core set of variables which all participating
countries have agreed to collect. Arriving at the final list
of variables to collect involved in-depth analysis of key
variables collected by other registries and formulation of
a comprehensive list of those variables (747 in total) and
a modified Delphi, consensus-driven approach to reduce
this list to 95 core variables, all overseen by a panel of 27
experts from 16 countries in the field of severe asthma.27
This final list of 95 core variables encompasses data on
patient demographics, medical history and diagnostics
(eg, peripheral blood and sputum eosinophil levels,
neutrophil levels and fractional exhaled nitric oxide),
clinical characteristics, patient-reported outcomes, and
treatment management plans.27 The core variable list
may also be added to with optional standardized safety
and effectiveness bolt-ons, capturing information ontors to ISAR, blue indicates the future contributors to ISAR, and orange
of abbreviation.
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severe infection, malignancies, anaphylaxis, additional
comorbidities, time of exacerbation, ICS/oral
corticosteroid dose, and reasons for medication
switching. Although the list is comprehensive, it is also
reduced to the minimum necessary to reduce data input
time and error, and to provide meaningful information
on severe asthma in real life. This may help to define a
link between best practices and improved outcomes and,
at the same time, ensure the sustainability of ISAR
moving forward.27 Local registries are free to collect
country-specific variables.
Organizational Structure
Currently, ISAR benefits from the support of three
collaborators. It is overseen by four governing bodies
safeguarding continuance of the registry into the future,
and ensuring ISAR research is ethical, clinically
appropriate, and continues to bring genuine value to
patients, public health, and health care. ISAR is a
registered data source on European Network of Centres
for Pharmacoepidemiology and Pharmacovigilance
asthma (http://www.encepp.eu/encepp/viewResource.
htm?id¼24389). The core collaborators currently
include the following: Optimum Patient Care Global
(OPC), the Respiratory Effectiveness Group (REG), and
AstraZeneca. OPC is an organization which specializes
in delivering medical research and services to improve
the diagnosis, treatment, and care of chronic diseases. It
has a long-standing record of delivering clinical support
services and global research by developing enhanced
quality databases and bespoke datasets for academic
research and global registries with the aim of improving
patient outcomes. REG is an investigator-led, not-for-
profit research initiative, promoting the value of real-life
research. ISAR’s four governing bodies include the ISAR
Steering Committee (ISC) (comprising 48 experts in
severe asthma research from 29 countries and medical
experts from AstraZeneca), REG, the Anonymized Data
Ethics & Protocol Transparency (ADEPT) Committee,
and the ISAR Operational Committee. The ADEPT
Committee is commissioned by REG to review ISAR
research protocols for their scientific quality and rigor.
The ISAR Operational Committee includes participating
country representatives (eg, country lead, deputy, data
managers) and is involved in the day to day running of
ISAR.
Data Capture
Electronic data capture (EDC) systems improve
efficiency, reduce workload, time, and cost, and enhance
the quality of data collected. ISAR data collection ischestjournal.orgsupported by the use of a dedicated template, and also
integrates with existing data capture systems (eg,
OpenClinica, REDCap, other country-specific systems).
These EDC systems ensure data quality via data
validation and editing at the point of data entry.
Automatic data validation rules are built into the EDC
platforms to minimize errors at data entry. The data are
secure and password-protected, and anonymized and
encrypted at source. Mandatory variables must be
entered, or a no data value imputed to confirm genuine
missing data, maximizing registry completeness and
minimizing bias. Furthermore, where possible, the ISAR
data capture process has been streamlined to maximize
efficiency. For example, patients may complete patient-
reported outcomes remotely in the comfort of their
homes or in the waiting room, and in certain countries
(eg, Denmark) the ISAR data capture template has been
embedded into electronic medical records, therefore
avoiding double-entry as much as possible, reducing the
administrative burden, and fulfilling a recent call for
greater integration between routine health-care records,
research databases, and biosamples.31
Inclusivity
ISAR operates under the principle of inclusivity and
openness. The ISAR doors are open to new collaborators
and partners using the Join Us or Register Interest
functions on the ISAR home page. Research ideas may
be suggested by ISC members, country leads, and
contributors and visitors to the ISAR webpage (which
includes third party commercial and academic research
organizations) by simply clicking the Submit Proposal or
Request Research tab. Each year all research ideas are
reviewed, selected, assessed for scientific rigor and
compliance with ethics standards, and prioritized by the
ISC. Other academic and commercial entities can seek
ISAR data access for research purposes, with all research
proposals requiring approval by both the ISC and
ADEPT.
Experience and Deliverables
ISAR holds within it the combined experience of 45 key
thought leaders, bringing together the severe asthma
knowledge from 29 countries. It benefits from the
capability of the OPC database management team
(which oversees one of the largest respiratory databases
in the world [Optimum Patient Care Research
Database]), ensuring the capture of high-quality data,
management of the dataset, and robust and ethical
scientific analyses. Finally, ISAR incorporates an
experienced communications team committed to809
ensuring timely dissemination of findings in
international, peer-reviewed journals and international
and regional scientific meetings.
In terms of deliverables, ISAR offers a unique
opportunity to observe the real-life severe asthma
situation and to assess the effectiveness, safety, and value
of new therapeutic agents (and existing ones), providing
valuable and complementary data to that obtained in the
more rigid and homogenous RCT environment. ISAR is
committed to producing a minimum of six datasets
annually. Core projects already commissioned include a
description of demographic and clinical characteristics
of patients with severe asthma worldwide, and
characterization of eosinophilic asthma
vs noneosinophilic phenotype. Other prioritized
research for the coming years is shown in Table 1. As
may be expected in severe asthma, there is a strong
research focus on biologics, but other topics are
considered just as important such as assessing hidden
severe asthma in primary care, the relationship between
socioeconomic status and asthma outcomes, and
characterization of health disparities across countries.
Limitations and Advantages of Registry Data
As an unavoidable consequence of their design, data
obtained from registries possess lower internal validityTABLE 1 ] ISAR Global Core Projects and Prioritized Resea
Description
Global core projects
Demographic and clinical baseline characteristics of patients
Characterization and comparison of eosinophilic and noneosin
Comparative effectiveness across severe asthma biologic clas
modalities
Prioritized research
Hidden patients with severe asthma in primary care vs ISAR
Impact of exacerbation burden on lung function trajectory in
Biologics in severe asthma: utilization patterns, causes for di
Biomarker Relatability in the International Severe Asthma Re
Identification of predictors (ie, biomarkers) of response to bio
Hidden chronic asthma within the COPD/ACO population
Age at onset of asthma in patients with severe asthma
Relationship between socioeconomic status and asthma outc
Describe the OCS landscape: annual consumption, prevalenc
Characterization of health disparities (burden of illness or mo
Criteria for choosing and switching between similar biologic tre
eosinophilic asthma
Describe the characteristics of patients with severe asthma w
ACO ¼ asthma-COPD overlap; ISAR ¼ International Severe Asthma Registry;
810 CHEST Reviewsthan RCTs, limiting the extent to which they can
demonstrate a cause-and-effect relationship. A major
challenge is the bias inherent in its volume, knowing
what to look for and how to assess and analyze large
amounts of data.32 Bias can be minimized by identifying
eligible populations; by controlling the study design,
study outcomes, and potential confounding factors (eg,
missing data) before work commences; and by using
rigorous analytic methods.33 Additionally, a database is
only as good as its data (ie, what is measured, in whom,
how is it measured and recorded). A system to routinely
validate and verify data integrity is essential to ensure
database utility.34 Because the patients included in ISAR
are those from tertiary centers (rather than from
primary care), we expect that they all have asthma.
There is the possibility, however, that some patients may
have asthma-COPD overlap. An ISAR prioritized
research project aims to describe the extent of asthma-
COPD overlap in this severe asthma population.
Furthermore, although North, Central and South
America, Europe and the Asia-Pacific region are well
represented within ISAR, there are still gaps in the global
cover (eg, Africa). We continue to reach out to countries
in these regions with existing registries, and are
committed to providing assistance to those countries
wishing to set up their own registry. The ultimate aim isrch
with severe asthma worldwide
ophilic phenotypes
ses (anti-IL-5 vs anti-IgE) in patients eligible for both
a broad asthma population and severe asthma population
scontinuation and switching, and adverse outcomes
gistry
logics
omes
e, outcomes, and side effects of long-term OCS users
rtality) across countries
atment options in patients with atopic and nonatopic severe
ith inflammatory phenotypes and FEV1 < 40%
OCS ¼ oral corticosteroid.
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to make the ISAR software available open source to
assist in the endeavor. Finally, merging data from
preexisting registries brings its own challenges, including
intercountry variability in the type of patients included
in registries, referral patterns, and service access.
Understanding the nature of each preexistent registry is
important before drawing conclusions.
On the other hand, data entered into registries are not
subjected to the same rigorous inclusion and exclusion
criteria required for RCTs. This results in high patient
numbers allowing comparisons between regions,
countries, continents, and populations. Registries are
population based and not subjected to the same sample
size statistical limitations of RCTs. Registry data are also
more heterogeneous in nature (than RCTs) and more
representative of patients seeking medical advice in real
life.33 The data are not biased by changing patient/
physician interaction, modification in health-care access,
treatment(s) prescribed, or outcomes assessed in any
way. An assessment of effect over a long period of time
may also be better answered using registry data, which is
precluded in RCTs because of cost. Registry data may be
collected prospectively or retrospectively, and because
these data are routinely collected, results can often be
obtained more quickly and at a lower cost than RCTs.33
ISAR Vision and Conclusions
ISAR is a real-life registry with lower internal validity
than clinical trial populations but extremely high
external validity to the severe asthma population
worldwide, as defined by the European Respiratory
Society/American Thoracic Society criteria. It permits
the implementation of existing knowledge in the severe
asthma population, generation of new knowledge, and
identification of the unknown, promoting new research.
Because the severe asthma population is relatively small
and heterogeneous, large numbers are needed to
understand the complexities of cause, biological/clinical
features, and outcomes, to provide personalized and
targeted care. By combining data from small registries
into one large standardized registry, comprising the
same set of variables with similar data structures, we are
able to compare and contrast differences between
countries and care systems, something which is not
currently possible in the global severe asthma
framework. ISAR has the potential to robustly interpret
and generally apply observations, but as it continues to
grow, the aim is to no longer simply estimate, but rather
to describe, the population in its entirety. ISAR’s
potential lies not so much in its ability to provide insightchestjournal.orginto asthma mechanisms, but rather in the information
it provides for improving diagnosis, disease stratification
(endotypes and phenotypes), and potentially the
identification of new targets for treatment, an approach
which is predictive, preventive, personalized, and
participatory.35 The challenge remains to harness ISAR’s
global data to provide meaningful clinical insight, and to
translate this knowledge into better diagnosis and
personalized care.32 Generation of new knowledge will
enable us to make the best choices for individual
patients, providing the best treatment at the individual
level (ie, the right treatment at the right time to the right
patient), therefore making a meaningful and beneficial
difference to the lives of patients with severe asthma
around the world. By identifying the unknown, ISAR
provides a fertile ground to do research to understand
both the disease and the impact of current and new
therapies.
Moving beyond ISAR, there is enormous potential to
link ISAR with other databases (eg, with primary care
data to find hidden severe asthma) to reduce the burden
and cost of regularly scheduled visits in tertiary care
centers, and to even link with other specialist databases/
registries (eg, COPD) to gain further insight for patients
with comorbidities. Data provided by ISAR may also be
helpful in supporting, modifying, and improving current
severe asthma guidelines. In the future, ISAR may be
more fully linked with electronic health records to
streamline data collection, and may also be linked with
patient-reported outcomes, helping patients and
physicians to make better personalized decisions.
Knowledge gathered by ISAR from patients with severe
asthma may be used to improve the management of
those with moderate disease (eg, to ascertain whether
better care earlier may lead to better outcomes later).
The ISAR database could also be used to investigate the
effectiveness of novel approaches to asthma treatment or
indeed the feasibility of new asthma treatment
paradigms. For example, the proposed paradigm of
regular treatment with biologics (in those patients likely
to respond), concomitant reduction of ICS dose, and use
of dual or triple combination therapy as a reliever on an
as-needed basis deserves investigation.36 ISAR could be
used not only to examine asthma outcomes and identify
patients likely to benefit, but also to assess the cost-
effectiveness of the approach. Potential benefits are
many and include improved adherence and asthma
control, fewer ICS-related side effects, and provision of a
validated simplified asthma management program
offering greater convenience for patients.36811
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